Reported 1 day ago
Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, although no binding agreement has yet been reached. Meanwhile, BridgeBio Pharma has received EU approval for its drug Beyonttra for transthyretin amyloidosis with cardiomyopathy, triggering a $75 million milestone payment from Bayer. Other updates include Biohaven's upcoming FDA decision on a treatment for spinocerebellar ataxia and Third Harmonic Bio's strategic restructuring as it moves toward Phase 2 testing for its drug THB335.
Source: YAHOO